Sintx Technologies Inc Stock Price, News & Analysis

SINTX Technologies (NASDAQ: SINT) announced significant changes to its Board of Directors as part of its strategic transformation into a focused medical technology business. Key changes include:

- Dr. B. Sonny Bal's retirement as Chairman after serving since 2012
- Appointment of current President and CEO Eric Olson as Chairman of the Board
- Jay Moyes named as Lead Independent Director
- Addition of four new directors:

• Chris Lyons - 35+ years in musculoskeletal and spine markets
• Robert Mitchell - 30+ years in global medical device leadership
• Mark Anderson - 35+ years at Boston Scientific across multiple divisions
• Gregg Honigblum - Chief Strategy Officer with extensive funding experience

The new board brings combined expertise in orthopedics, spine, interventional pain, cardiovascular, medical device business development, and global commercialization.

SINTX Technologies (NASDAQ: SINT) announced the publication of a peer-reviewed study demonstrating the biomechanical advantages of silicon nitride in anterior cervical discectomy and fusion (ACDF) procedures. The research, conducted by SRM Institute of Science and Technology in collaboration with SINTX, compared various cage designs and materials used in cervical spine fusion.

The study highlighted several key advantages of silicon nitride over traditional materials like PEEK and titanium:

• Reduced cage subsidence and exceptional load-bearing capability
• Enhanced stress distribution and lower risk of adjacent segment degeneration
• Superior osseointegration properties compared to biologically inert PEEK
• Better post-surgical imaging capabilities due to radiolucency

With global spinal fusion procedures expected to exceed $10 billion annually, SINTX aims to leverage these findings to expand the adoption of silicon nitride-based medical devices in orthopedic applications.

Sintx Technologies (NASDAQ: SINT) announced a significant leadership transition as Dr. Sonny Bal retires from his position as Chairman of the Board, with CEO Eric Olson unanimously appointed as the new Chairman, effective immediately.

Dr. Bal, who served as Chairman since 2015, will remain on the Board of Directors to ensure continuity. Under his leadership, Sintx underwent transformation in the advanced materials sectors, particularly focusing on high-value medical applications and strategic partnerships.

Eric Olson, who became CEO in August 2024, brings experience in medical device and industrial sectors. His appointment as Chairman aligns with the company's strategy to accelerate commercialization, enhance financial discipline, and explore strategic initiatives including partnerships, licensing, and M&A opportunities.

SINTX Technologies (NASDAQ: SINT) has completed a $5 million private placement with institutional and accredited investors, priced at-the-market under Nasdaq rules. The company issued 1,449,287 shares of common stock at $3.45 per share, along with unregistered warrants to purchase an equal number of shares at $3.32 per share.

The warrants are immediately exercisable and will expire in five and a half years. H.C. Wainwright & Co. served as the exclusive placement agent. The net proceeds, after deducting fees and expenses, will be used for working capital purposes.

The securities were offered under Section 4(a)(2) of the Securities Act and Regulation D, exclusively to accredited investors. SINTX has agreed to file registration statements with the SEC for the resale of the common stock and shares issuable upon warrant exercise.

SINTX Technologies (NASDAQ: SINT) has announced the sale of its subsidiary, Technology Assessment and Transfer (TA&T), to Tethon This strategic move aims to streamline operations and focus on the medical device sector, particularly in bioceramic technologies for healthcare applications.

The transaction provides significant financial benefits, reducing corporate liabilities by $750,000 and cutting annual operating expenses by over $1.7 million. The company will concentrate on commercializing its silicon nitride-based technologies, which have been utilized in human implants since 2008.

According to CEO Eric K. Olson, this divestment represents a strategic realignment that will enable SINTX to commit its resources fully to the medical device market, where their advanced ceramics expertise can make the most significant impact.

SINTX Technologies (NASDAQ: SINT) has been granted U.S. Patent No. 12,239,761 by the USPTO, strengthening its intellectual property portfolio in silicon nitride innovation. The patent covers novel methods of adhering silicon nitride to various biomaterial substrates, enhancing biocompatibility and infection resistance in medical implants.

As the only FDA-registered producer of implantable silicon nitride, SINTX's technology portfolio includes monolithic ceramic implants, particulate-based coatings, microspheres, and composite materials. The company's innovations focus on improving osseointegration and reducing bacterial colonization in orthopedic, craniomaxillofacial, dental, and spinal implants.

The company's intellectual property portfolio now comprises 17 issued U.S. patents and 84 pending applications worldwide.

SINTX Technologies (NASDAQ: SINT) has received a Notice of Allowance from the USPTO for patent application no. 17/237,687, titled 'Methods of Silicon Nitride Laser Cladding.' The patent covers a method for laser bonding bioactive silicon nitride to various biomedical implant substrates, including titanium, alumina, zirconia, and advanced polymers.

This technology complements their recently granted U.S. Patent (US 12162807) and enhances traditional implant materials with silicon nitride's osseointegration and bacterial resistance properties. As the only FDA-registered producer of implantable silicon nitride, SINTX has developed the material in both monolithic and particulate forms for various applications.

The company's intellectual property portfolio now includes 17 issued U.S. patents and 84 pending patent applications worldwide.

SINTX Technologies (NASDAQ: SINT) has signed a Joint Development Agreement with NED Medical to develop advanced ceramic-based microspheres for cancer treatment. The collaboration focuses on manufacturing microspheres containing Yttrium-90 radioisotope for transarterial radioembolization (TARE) treatment of hepatocellular carcinoma. The engineered microspheres, known as CombiSphere, feature unique properties including radiopacity and porosity, allowing for targeted chemotherapy and combination therapies. SINTX will support NED Medical's pre-clinical testing needs and transition the microsphere process from R&D to pilot production.